GuruFocus.com8d agoneutral
Novo Nordisk Stock Rises After GLP-1 Antitrust WinDismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
52last 24h
1809last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
GuruFocus.com8d agoneutral
Lilly and Novo Win a Key GLP-1 Antitrust FightA Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.
BioPharma Dive23d agoneutral
Lilly, with new data, to seek FDA approval of obesity drug retatrutideThe new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.